SBIR Phase I: Semisynthetic Synthesis of Mutacin 1140

Information

• NSF Award
• 0419205

Owner

• ORAGENICS, INC.

• Award Id

  0419205

• Award Effective Date

  7/1/2004 - 20 years ago

• Award Expiration Date

  12/31/2004 - 19 years ago

• Award Amount

  $ 100,000.00

• Award Instrument

  Standard Grant

This Small Business Innovation Research (SBIR) Phase I project will develop new preparative strategies for the peptide antibiotic Mutacin 1140 and related derivatives. Current fermentation and synthetic routes are impractical. In-vitro testing suggests that Mutacin and its derivatives may work on drug-resistant bacterial strains. The peptide backbone of the antibiotic will be produced by cloning and expressing a 22mer artificial gene. The structure will then be modified to a range of derivatives synthetically.<br/><br/>The commercial application of the proposed project is in the area of antibiotics to combat human infectious diseases. Screening has indicated effectiveness against a wide range of gram positive and some gram-negative pathogens including multidrug resistant strains of Staphylococcus aureus.

• Program Officer

  Om P. Sahai

• Min Amd Letter Date

  6/10/2004 - 20 years ago

• Max Amd Letter Date

  6/10/2004 - 20 years ago

• ARRA Amount

• Name

  Oragenics Corporation

• City

  ALACHUA

• State

  FL

• Country

  United States

• Address

  13700 Progress Blvd.

• Postal Code

  326159496

• Phone Number

  3864184018

• First Name

  Jeffrey

• Last Name

  Hillman

• Email Address

  jhillman@oragenics.com

• Start Date

  6/10/2004 12:00:00 AM

• Name

  Industrial Technology

• Code

  308000